Form 8-K - Current report:
SEC Accession No. 0001193125-25-044406
Filing Date
2025-03-04
Accepted
2025-03-03 18:25:47
Documents
17
Period of Report
2025-03-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d909216d8k.htm   iXBRL 8-K 32891
2 EX-1.1 d909216dex11.htm EX-1.1 184188
3 EX-5.1 d909216dex51.htm EX-5.1 7145
7 GRAPHIC g909216dsp6a.jpg GRAPHIC 2444
8 GRAPHIC g909216g0226151504775.jpg GRAPHIC 2491
  Complete submission text file 0001193125-25-044406.txt   417091

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20250303.xsd EX-101.SCH 2855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20250303_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20250303_pre.xml EX-101.PRE 11264
20 EXTRACTED XBRL INSTANCE DOCUMENT d909216d8k_htm.xml XML 3670
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 25700545
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)